INTRODUCTION: The aim of this study was to compare the concentration of serum Brain-derived neurotrophic factor (BDNF) in patients suffering from major depressive disorder (MDD) considering the severity of MDD episode defined by the Hamilton rating scale for depression (HAMD-17). The other aim was to research the connection between serum BDNF and the symptomatic dimensions of MDD. SUBJECTS AND METHODS: The study includes 139 participants with major depressive disorder (MDD). Diagnosis of MDD was set by DSM-IV-TR criteria. The severity of MDD was estimated with HAM-D-17 in the manner that mild episode was diagnosed if the score on HAMD-17 was up to 18, moderately severe 18-25 and severe over 25. Concentration of BDNF was determined by the ELISA method. RESULTS: This research could not find a difference in BDNF concentration considering the severity of the depressive disorder in groups suffering from mild, moderately severe and severe episodes of MDD (F=1.816; p=0.169). Factor analysis of HAMD-17 extracted four dimensions of depressive symptoms. None of the symptomatic dimensions was significantly related to BDNF concentration. CONCLUSION: Results of this study indicate that serum BDNF levels are not related to the severity of depression and its specific symptomatic dimensions. These findings support the idea of a complex relationship between BDNF concentration at the periphery and in the CNS.
INTRODUCTION: The aim of this study was to compare the concentration of serum Brain-derived neurotrophic factor (BDNF) in patients suffering from major depressive disorder (MDD) considering the severity of MDD episode defined by the Hamilton rating scale for depression (HAMD-17). The other aim was to research the connection between serum BDNF and the symptomatic dimensions of MDD. SUBJECTS AND METHODS: The study includes 139 participants with major depressive disorder (MDD). Diagnosis of MDD was set by DSM-IV-TR criteria. The severity of MDD was estimated with HAM-D-17 in the manner that mild episode was diagnosed if the score on HAMD-17 was up to 18, moderately severe 18-25 and severe over 25. Concentration of BDNF was determined by the ELISA method. RESULTS: This research could not find a difference in BDNF concentration considering the severity of the depressive disorder in groups suffering from mild, moderately severe and severe episodes of MDD (F=1.816; p=0.169). Factor analysis of HAMD-17 extracted four dimensions of depressive symptoms. None of the symptomatic dimensions was significantly related to BDNF concentration. CONCLUSION: Results of this study indicate that serum BDNF levels are not related to the severity of depression and its specific symptomatic dimensions. These findings support the idea of a complex relationship between BDNF concentration at the periphery and in the CNS.
Authors: Na Yang; Elizabeth Levey; Bizu Gelaye; Qiu-Yue Zhong; Marta B Rondon; Sixto E Sanchez; Michelle A Williams Journal: Arch Womens Ment Health Date: 2017-07-27 Impact factor: 3.633
Authors: Martin Helan; Bharathi Aravamudan; William R Hartman; Michael A Thompson; Bruce D Johnson; Christina M Pabelick; Y S Prakash Journal: J Mol Cell Cardiol Date: 2014-01-23 Impact factor: 5.000
Authors: Anatoly Kreinin; Serah Lisson; Elimelech Nesher; Jenny Schneider; Josef Bergman; Kamal Farhat; Joseph Farah; Flavio Lejbkowicz; Gal Yadid; Leon Raskin; Igor Koman; Albert Pinhasov Journal: PLoS One Date: 2015-05-26 Impact factor: 3.240
Authors: Jenny Fung; Bizu Gelaye; Qiu-Yue Zhong; Marta B Rondon; Sixto E Sanchez; Yasmin V Barrios; Karin Hevner; Chunfang Qiu; Michelle A Williams Journal: BMC Psychiatry Date: 2015-03-10 Impact factor: 3.630
Authors: Juan Joseph Young; Tim Silber; Davide Bruno; Isaac Robert Galatzer-Levy; Nunzio Pomara; Charles Raymond Marmar Journal: Front Psychiatry Date: 2016-04-25 Impact factor: 4.157